Previous Close | 33.46 |
Open | 33.48 |
Bid | 34.93 x 900 |
Ask | 34.97 x 1200 |
Day's Range | 33.36 - 35.12 |
52 Week Range | 25.98 - 47.49 |
Volume | |
Avg. Volume | 1,490,331 |
Market Cap | 3.428B |
Beta (5Y Monthly) | 0.57 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -5.55 |
Earnings Date | Feb 28, 2024 - Mar 04, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 60.89 |
Subscribe to Yahoo Finance Plus to view Fair Value for CYTK
As Previously Announced, Reldesemtiv Had No Effect on the Primary Endpoint of Change from Baseline in ALSFRS-R or Key Secondary Endpoints Trial Discontinued in March 2023 Due to Futility Following Second Planned Interim Analysis Survey Reveals Site Personnel and Patients Have Favorable View of Trial Features to Reduce Burden of Participation SOUTH SAN FRANCISCO, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the full results of COURAGE-AL
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 30, 2023 it granted stock options to purchase an aggregate of 25,350 shares of common stock to two new employees, whose employment commenced in November 2023, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $33.48 per share, which is equal to the closing price of the Company’s common stock o
Results from COURAGE-ALS to Be Presented on December 7, 2023SOUTH SAN FRANCISCO, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five presentations at the 34th International Symposium on ALS/MND taking place in Basel, Switzerland and online from December 6, 2023 - December 8, 2023. Oral Presentations Title: Site and Participant Perspectives on Participating in an ALS Trial Designed to Reduce Burden: COURAGE-ALSPresenter: Stacy Rudnicki, M.D., V